Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2013 · 10-Q
Revenue$676.00K$676.00K+215.9% vs Q2 2012 Net Income-$26.03M-$26.03MN/M vs Q2 2012 EPS Diluted-$0.35-$0.35N/M vs Q2 2012 Operating Income-$26,111,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,666,000N/M Margins · derivedOperating margin-3862.6%+9513.1 pt vs Q2 2012
Net margin-3850.3%+9738.5 pt vs Q2 2012
ended Jun 30, 2014 · filed Aug 7, 2014 · 38 d after period end